Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine

Abstract

Objective: At present there is no established optimal approach for transitioning opioid-dependent adults to extended-release injection naltrexone (XR-naltrexone) while preventing relapse. The authors conducted a trial examining the efficacy of two methods of outpatient opioid detoxification for induction to XR-naltrexone.

Method: Participants were 150 opioid-dependent adults randomly assigned 2:1 to one of two outpatient detoxification regimens, naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of XR-naltrexone. Naltrexone-assisted detoxification lasted 7 days and included a single day of buprenorphine followed by ascending doses of oral naltrexone along with clonidine and other adjunctive medications. Buprenorphine-assisted detoxification included a 7-day buprenorphine taper followed by a week-long delay before administration of XR-naltrexone, consistent with official prescribing information for XR-naltrexone. Participants from both groups received behavioral therapy focused on medication adherence and a second dose of XR-naltrexone.

Results: Compared with participants in the buprenorphine-assisted detoxification condition, participants assigned to naltrexone-assisted detoxification were significantly more likely to be successfully inducted to XR-naltrexone (56.1% compared with 32.7%) and to receive the second injection at week 5 (50.0% compared with 26.9%). Both models adjusted for primary type of opioid use, route of opioid administration, and morphine equivalents at baseline.

Conclusions: These results demonstrate the safety, efficacy, and tolerability of low-dose naltrexone, in conjunction with single-day buprenorphine dosing and adjunctive nonopioid medications, for initiating adults with opioid dependence to XR-naltrexone. This strategy offers a promising alternative to the high rates of attrition and relapse currently observed with agonist tapers in both inpatient and outpatient settings.

Trial registration: ClinicalTrials.gov NCT01377610.

Keywords: Buprenorphine; Detoxification; Injectable Naltrexone; Naltrexone; Opioid Dependence; Outpatient.

Conflict of interest statement

Disclosures

All remaining authors report no financial relationships with commercial interests.

Figures

Figure 1

CONSORT diagram of participants in a controlled study of oral naltrexone vs. buprenorphine as detoxification strategies for induction onto extended-release naltrexone in opioid-dependent adults

Figure 2

Longitudinal observed daily proportion of participants with at least mild withdrawal on average (mean Clinical Opiate Withdrawal Scale ≥ 5), by treatment arm (Figure 2A); longitudinal observed daily proportion of participants with at least one report of moderate-severe withdrawal (maximum Clinical Opiate Withdrawal Scale ≥ 12) by treatment arm (Figure 2B).

Figure 3

Longitudinal Clinical Opiate Withdrawal Scale (Figure 3A) and Hamilton Depression Rating Scale (Figure 3B) scores during weeks after XR-naltrexone induction, by treatment arm.a aError bars indicate standard deviation.